Companies / BOC Sciences / Zilovertamab
BOC Sciences

Zilovertamab | BOC Sciences

Zilovertamab is a first-in-class humanized monoclonal antibody that binds to ROR1. Zilovertamab has been undergoing clinical trials in combination with ibrutinib for the treatment of mantle cell lymphoma (MCL) and chronic lymphocytic leukemia (CLL).

Reviews


No reviews yet

ABOUT THE COMPANY

BOC Sciences specializes in small molecule synthesis, biosynthesis, purification, and characterization. It provides a wide range of research chemicals and biochemicals, including inhibitors, building blocks, carbohydrates, nucleosides, nucleotides, GMP Products, impurities and metabolites, APIs, natural compounds, ADCs, stem cell molecules and chiral compounds.
  • See More